Follow The Filings

SGMT Sagimet Biosciences

Sagimet Biosciences earnings company data as of 4:48 AM ET 10/23

Limited consensus data for this ticker (thin coverage or data-plan limits). Dates may be company-announced rather than sell-side consensus. Calendar and recent prints remain the primary lens when available.

Scheduled

1 period, newest first, nothing reported yet. Each row shows EPS above revenue.

Period Date Metric Estimate Actual Result
FY2026 Q3 12 Nov EPS — — —
Rev — — —

Insider trades

Open-market buys and sales by SGMT's executives, directors and 10% owners in the last 12 months, from their Form 4s

All SGMT insider trades
  • None no insider bought on the open market
  • None no sales outside a trading plan
  • $4.2M sold by 1 insider under 10b5-1 plans
  1. George Kemble Director
    Planned sale
    $3.6M 350,987 shares at $10.23 85% of stake
    Traded Aug 14 Filed Aug 17
  2. George Kemble Director
    Planned sale
    $201K 20,206 shares at $9.95 25% of stake
    Traded Aug 11 Filed Aug 12
  3. George Kemble Director
    Planned sale
    $141K 18,844 shares at $7.46 23% of stake
    Traded Jul 20 Filed Jul 22
  4. George Kemble Chair
    Planned sale
    $290K 37,688 shares at $7.69 32% of stake
    Traded Nov 20, 2025 Filed Nov 21, 2025

Also filed in the last 12 months, not counted as buying or selling: 6 sales to cover taxes, 5 stock grants, and 4 option exercises.

SEC filings

Recent issuer filings from EDGAR, 24 shown.

Filed Form Detail Links
8-K 7.01,9.01
SCHEDULE 13G —
424B5
8-K 1.01,9.01
424B3
8-K 7.01,8.01,9.01
SCHEDULE 13G —
8-K 8.01
10-Q
8-K 2.02,7.01,9.01
SCHEDULE 13G —
8-K 7.01,9.01
8-K 5.02,5.07
8-K 5.02,9.01
10-Q
8-K 2.02,9.01
424B5
8-K 1.01,9.01
8-K 2.02,7.01,8.01,9.01
8-K 7.01,9.01
DEF 14A
8-K 5.02,8.01
10-K
8-K 2.02,7.01,9.01

Estimates are consensus figures; SEC filings remain the official record. Not investment advice.